Danelle James

Danelle James, MD, is the Head of Clinical Development and Medical Affairs. She has the primary responsibility for the clinical development of Summit’s pipeline candidates and Summit’s external education and awareness strategy.

Most recently, Dr. James was the Global Development Lead for IMBRUVICA® (ibrutinib) for Pharmacyclics, an AbbVie Company, after joining Pharmacyclics in 2011. She worked to launch and expand IMBRUVICA® (ibrutinib) globally through scientific oversight and execution of the very broad clinical development program. Prior to Pharmacyclics, Dr. James was a faculty member in the Department of Medicine, Division of Hematology and Oncology, at the University of California San Diego. Her research focus at UCSD for almost ten years, was the study of the Chronic Lymphocytic Leukemia (CLL), non-Hodgkin’s lymphoma, the tumor microenvironment, and the clinical-translational development of agents that can be used to target these interactions. Dr. James started her career in industry approximately 20 years ago at Biogen in Cambridge, Massachusetts, where she worked in the Department of Immunology and Inflammation.

Dr. James has published over 50 peer-reviewed manuscripts. She received her MD from Penn State University College of Medicine and completed her Internal Medicine residency and Hematology / Oncology fellowship at UCSD; she is Board Certified in Internal Medicine and in Hematology. Dr. James obtained a Master of Science degree in Advanced Studies of Clinical Research from UCSD.